

Title (en)
ANTIBODIES AGAINST CSF-1R

Title (de)
ANTIKÖRPER GEGEN CSF-1R

Title (fr)
ANTICORPS ANTI-CSF-1R

Publication
EP 4282881 A3 20240221 (EN)

Application
EP 23192221 A 20140826

Priority
• GB 201315487 A 20130830
• EP 19171833 A 20140826
• EP 14755668 A 20140826
• EP 2014068050 W 20140826

Abstract (en)
The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.

IPC 8 full level
A61K 39/00 (2006.01); **A61P 11/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP IL US)
A61P 11/00 (2018.01 - EP IL US); **A61P 35/00** (2018.01 - EP IL US); **C07K 16/28** (2013.01 - IL); **C07K 16/2866** (2013.01 - EP IL US); **A61K 2039/505** (2013.01 - EP IL US); **C07K 2317/24** (2013.01 - EP IL US); **C07K 2317/33** (2013.01 - EP IL US); **C07K 2317/565** (2013.01 - IL US); **C07K 2317/76** (2013.01 - EP IL US); **C07K 2317/92** (2013.01 - EP IL US); **C07K 2317/94** (2013.01 - EP IL US)

Citation (search report)
• [I] WO 2011140249 A2 20111110 - FIVE PRIME THERAPEUTICS INC, et al
• [I] WO 2012110360 A1 20120823 - TRANSGENE SA [FR], et al
• [I] WO 2011070024 A1 20110616 - HOFFMANN LA ROCHE [CH], et al
• [I] WO 2013087699 A1 20130620 - HOFFMANN LA ROCHE [CH], et al
• [I] WO 2009026303 A1 20090226 - AMGEN INC [US], et al
• [I] LIM A K H ET AL: "Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice", DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, vol. 52, no. 8, 23 May 2009 (2009-05-23), pages 1669 - 1679, XP019735325, ISSN: 1432-0428, DOI: 10.1007/S00125-009-1399-3
• [A] MACDONALD KELLI P A ET AL: "An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 19, 11 November 2010 (2010-11-11), pages 3955 - 3963, XP002671735, ISSN: 0006-4971
• [A] P. PAULUS ET AL: "Colony-Stimulating Factor-1 Antibody Reverses Chemoresistance in Human MCF-7 Breast Cancer Xenografts", CANCER RESEARCH, vol. 66, no. 8, 15 April 2006 (2006-04-15), pages 4349 - 4356, XP055149182, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-3523

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2015028455 A1 20150305; AR 097464 A1 20160316; AU 2014314304 A1 20160317; AU 2014314304 B2 20191205; BR 112016004324 A2 20171024; BR 112016004324 B1 20240116; CA 2922240 A1 20150305; CA 2922240 C 20230905; CL 2016000438 A1 20161111; CN 105658236 A 20160608; CN 105658236 B 20210319; CN 112321711 A 20210205; CY 1121964 T1 20201014; DK 3038643 T3 20190624; DK 3549599 T3 20231030; EA 036255 B1 20201020; EA 201690503 A1 20160630; EP 3038643 A1 20160706; EP 3038643 B1 20190501; EP 3549599 A1 20191009; EP 3549599 B1 20230906; EP 4282881 A2 20231129; EP 4282881 A3 20240221; ES 2733735 T3 20191202; ES 2965207 T3 20240411; FI 3549599 T3 20231031; GB 201315487 D0 20131016; HK 1220142 A1 20170428; HR P20191051 T1 20190906; HR P20231264 T1 20240202; HU E045672 T2 20200128; HU E064437 T2 20240328; IL 244043 A1 20160421; IL 244043 B 20210131; JP 2016529266 A 20160923; JP 2020005652 A 20200116; JP 2022002523 A 20220111; JP 6632075 B2 20200115; JP 7195237 B2 20221223; KR 102303130 B1 20210916; KR 20160044018 A 20160422; LT 3038643 T 20190725; LT 3549599 T 20231110; MA 38930 A1 20171229; MA 44922 A1 20190830; MA 44922 B1 20200630; MX 2016002166 A 20160623; MY 172484 A 20191126; NZ 717399 A 20211224; PE 20160528 A1 20160521; PE 20201067 A1 20201019; PH 12016500275 A1 20160502; PH 12016500275 B1 20160502; PL 3038643 T3 20191129; PL 3549599 T3 20240304; PT 3038643 T 20190725; PT 3549599 T 20231121; RS 59019 B1 20190830; RS 64784 B1 20231130; SG 11201601151P A 20160330; SI 3038643 T1 20190830; SI 3549599 T1 20231229; TN 2016000067 A1 20170705; TR 201909478 T4 20190722; TW 201512221 A 20150401; TW I531582 B 20160501; UA 118354 C2 20190110; US 10421814 B2 20190924; US 2016200821 A1 20160714; US 2018162947 A1 20180614; US 9908939 B2 20180306; UY 35718 A 20150327; ZA 201601437 B 20180829

DOCDB simple family (application)
EP 2014068050 W 20140826; AR P140103206 A 20140827; AU 2014314304 A 20140826; BR 112016004324 A 20140826; CA 2922240 A 20140826; CL 2016000438 A 20160225; CN 201480057403 A 20140826; CN 202011009068 A 20140826; CY 191100779 T 20190723; DK 14755668 T 20140826; DK 19171833 T 20140826; EA 201690503 A 20140826; EP 14755668 A 20140826; EP 19171833 A 20140826; EP 23192221 A 20140826; ES 14755668 T 20140826; ES 19171833 T 20140826; FI 19171833 T 20140826; GB 201315487 A 20140830; HK 16108335 A 20160715; HR P20191051 T 20190612; HR P20231264 T 20140826; HU E14755668 A 20140826; HU E19171833 A 20140826; IL 24404316 A 20160209; JP 2016537262 A 20140826; JP 2019166697 A 20190913; JP 2021152574 A 20210917; KR 20167007073 A 20140826; LT 14755668 T 20140826; LT 19171833 T 20140826; MA 38930 A 20140826; MA 44922 A 20140826; MX 2016002166 A 20140826; MY P12016700624 A 20140826; NZ 71739914 A 20140826; PE 2016000313 A 20140826; PE 2020000532 A 20140826; PH 12016500275 A 20160210; PL 14755668 T 20140826; PL 19171833 T 20140826; PT 14755668 T 20140826; PT 19171833 T 20140826; RS P20190833 A 20140826; RS P20230962 A 20140826; SG 11201601151P A 20140826; SI 201431235 T 20140826;

SI 201432048 T 20140826; TN 2016000067 A 20140826; TR 201909478 T 20140826; TW 103126815 A 20140805; UA A201601175 A 20140826;
US 201414914676 A 20140826; US 201815883130 A 20180130; UY 35718 A 20140829; ZA 201601437 A 20160302